Can-Fite BioPharma Ltd. (TLV:CANF)
Israel
· Delayed Price · Currency is ILS · Price in ILA 444.70
-8.70 (-1.92%)
Apr 28, 2026, 5:01 PM IDT
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
258.23K ILS
Profits / Employee
-6.27M ILS
Market Cap
19.06M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioLight Life Sciences | 4 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 10 |
| Evogene | 52 |
| BioLineRx | 24 |
| Matricelf | 15 |
| Geffen Residence & Renewal | 6 |
| Bonus BioGroup | 37 |
Can-Fite BioPharma News
- 4 weeks ago - Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs - GuruFocus
- 4 weeks ago - Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - GlobeNewsWire
- 4 weeks ago - Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - GlobeNewsWire
- 6 weeks ago - Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment - GuruFocus
- 6 weeks ago - Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance - GlobeNewsWire
- 7 weeks ago - Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants - Nasdaq
- 7 weeks ago - Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study - Benzinga
- 7 weeks ago - Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study - GuruFocus